On December 4, 2025, IDEAYA Biosciences, Inc. received notice from GSK to terminate their collaboration agreement, effective in 90 days, during which time IDEAYA will receive the Werner Helicase (IDE275) and Pol Theta (IDE705) clinical programs and evaluate options for them in 2026. The company still expects its cash runway to last into 2030.